Characterizing the interaction modes of PAR4 receptor with agonist and antagonist by molecular simulation approach

被引:0
作者
Lu, Nan [1 ,2 ]
Meng, Fancui [2 ]
Yuan, Jing [2 ]
Liu, Lei [2 ]
Wang, Yanshi [2 ]
Li, Lingjun [2 ]
Zhao, Tong [2 ]
Xu, Weiren [2 ]
Tang, Lida [2 ]
Xu, Youjun [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Liaoning, Peoples R China
[2] Tianjin Inst Pharmaceut Res, Tianjin Key Lab Mol Design & Drug Discovery, Tianjin 300193, Peoples R China
关键词
PAR4; molecular docking; molecular dynamics; agonist; antagonist; PLATELET ACTIVATION; PROTEIN-STRUCTURE; IONIC LOCK; GENERATION; MECHANISM; EFFICIENT; PEPTIDE; BINDING;
D O I
10.1142/S0219633619500081
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Protease-activated receptor 4 (PAR4) is a promising target for antiplatelet therapy. In this study, homology modeling and molecular docking methods were used to investigate the binding modes of PAR4 agonists and antagonists. The outcomes show that agonists have good docking scores, and they also form more hydrogen bonds with PAR4 than antagonists. To reveal the different conformational changes caused by agonist and antagonist, molecular dynamic simulations were carried out on three selected PAR4 systems. Simulation results show that PAR4 activation involves breaking interactions of 3-7 lock switch (Try157 and Tyr322) and ionic lock switch (Arg188 and Asp173), and formation of transmission switch among Tyr161, Asn300 and Phe296. In addition, principal component analysis (PCA) indicates that the major change for agonist bound system takes place in the intracellular region while that for antagonist bound system is in the extracellular region. The binding free energy of BMS-986120 is much lower than AYPGKF, suggesting high affinity of antagonist. Moreover, the electronegative aspartic residues Asp230 and Asp235 at ECL2 are important for PAR4 binding to agonist. Clarifying the PAR4 structural characteristics may be helpful to understand the activation mechanism, giving insights into the molecular design and discovery of novel potential PAR4 antagonists in the future.
引用
收藏
页数:17
相关论文
共 40 条
[1]   Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers [J].
Abraham, Mark James ;
Murtola, Teemu ;
Schulz, Roland ;
Páll, Szilárd ;
Smith, Jeremy C. ;
Hess, Berk ;
Lindah, Erik .
SoftwareX, 2015, 1-2 :19-25
[2]   High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation [J].
Altenbach, Christian ;
Kusnetzow, Ana Karin ;
Ernst, Oliver P. ;
Hofmann, Klaus Peter ;
Hubbell, Wayne L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (21) :7439-7444
[3]  
[Anonymous], **DROPPED REF**
[4]  
[Anonymous], 2009, PRIM VERS 3 0
[5]   Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 [J].
Ballesteros, JA ;
Jensen, AD ;
Liapakis, G ;
Rasmussen, SGF ;
Shi, L ;
Gether, U ;
Javitch, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :29171-29177
[6]   A cluster of aspartic residues in the extracellular loop II of PAR 4 is important for thrombin interaction and activation of platelets [J].
Centellas, Daniel Sanchez ;
Gudlur, Sushanth ;
Vicente-Carrillo, Alejandro ;
Ramstrom, Sofia ;
Lindahl, Tomas L. .
THROMBOSIS RESEARCH, 2017, 154 :84-92
[7]   Insights into the binding of agonist and antagonist to TAS2R16 receptor: a molecular simulation study [J].
Chen, Zhirong ;
Dong, Shifen ;
Meng, Fancui ;
Liang, Yaoyue ;
Zhang, Shuofeng ;
Sun, Jianning .
MOLECULAR SIMULATION, 2018, 44 (04) :322-329
[8]   Proteinase-activated receptors (PARs) as targets for antiplatelet therapy [J].
Cunningham, Margaret ;
McIntosh, Kathryn ;
Bushell, Trevor ;
Sloan, Graeme ;
Plevin, Robin .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 :606-612
[9]   Protease-activated receptor 4: from structure to function and back again [J].
French, Shauna L. ;
Hamilton, Justin R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (20) :2952-2965
[10]   Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent [J].
French, Shauna L. ;
Arthur, Jane F. ;
Tran, Huyen A. ;
Hamilton, Justin R. .
BLOOD REVIEWS, 2015, 29 (03) :179-189